Skip to main content
SpringerLink
Log in

Optimal Management of Nasal Congestion Caused by Allergic Rhinitis in Children

Safety and Efficacy of Medical Treatments

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Nasal congestion is such a frequent and multifactorial occurrence in young children that parents and medical caregivers often overlook the need for medical intervention. However, children with congestion can suffer quality-of-life detriments resulting from sleep disturbance, learning impairment, and fatigue. Congestion also impairs the normal nasal breathing that is physiologically important for the efficient cleaning and conditioning of inspired air. Further, the most common cause of congestion, allergic rhinitis, is considered a potential risk factor for asthma.

Published guidelines on the treatment of allergic rhinitis agree that management strategies in children should follow the same principles as in adults, while recognizing the need for dosage adjustments and being aware of unique safety issues. Intranasal corticosteroids, with robust effects in reducing congestion and good tolerability, remain a treatment of choice. Despite lingering concerns about the potential for growth suppression with these drugs, clinical evidence suggests a very low risk at prescribed dosages, especially with compounds that have a low systemic bioavailability.

Oral antihistamines are commonly cited as first-line options for allergic rhinitis, although their effect on nasal congestion is relatively modest. First-generation antihistamines should not be administered to children because of their sedative properties, which can worsen learning problems associated with allergic rhinitis. Second-generation oral antihistamines are preferred, although this class is not completely devoid of adverse effects. Other treatments, such as a nasal antihistamine, decongestants, and immunotherapy, present varying levels of safety and tolerability issues in children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Fig. 1
Table V
Table VI

Similar content being viewed by others

References

  1. Rajagopal MR, Paul J. Applied anatomy and physiology of the airway and breathing. Indian J Anaesth 2005; 49: 251–6

    Google Scholar 

  2. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999; 204: 209–13

    Article  Google Scholar 

  3. Shturman-Ellstein R, Zeballos RJ, Buckley JM, et al. The beneficial effect of nasal breathing on exercise-induced bronchoconstriction. Am Rev Respir Dis 1978; 118: 65–73

    PubMed  CAS  Google Scholar 

  4. Griffin MP, McFadden Jr ER, Ingram Jr RH. Airway cooling in asthmatic and nonasthmatic subjects during nasal and oral breathing. J Allergy Clin Immunol 1982; 69: 354–9

    Article  PubMed  CAS  Google Scholar 

  5. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478–518

    Article  PubMed  CAS  Google Scholar 

  6. Berger WE. Allergic rhinitis in children: diagnosis and management strategies. Paediatr Drugs 2004; 6: 233–50

    Article  PubMed  Google Scholar 

  7. Corey JP, Houser SM, Ng BA. Nasal congestion: a review of its etiology, evaluation, and treatment. Ear Nose Throat J 2000; 79: 690–3, 6, 8

    PubMed  CAS  Google Scholar 

  8. American Academy of Pediatrics Subcommittee on Management of Sinusitis and Committee on Quality Improvement. Clinical practice guideline: management of sinusitis. Pediatrics 2001; 108: 798–808

    Google Scholar 

  9. Fireman P. Therapeutic approaches to allergic rhinitis: treating the child. J Allergy Clin Immunol 2000; 105: S616–21

    Article  PubMed  CAS  Google Scholar 

  10. Gelfand EW. Pediatric allergic rhinitis: factors affecting treatment choice. Ear Nose Throat J 2005; 84: 163–8

    PubMed  Google Scholar 

  11. Meltzer EO. Treatment options for the child with AR. Clin Pediatr 1998; 37: 1–10

    Article  CAS  Google Scholar 

  12. Druce HM, Kaliner MA. Allergic rhinitis. JAMA 1988; 259: 260–3

    Article  PubMed  CAS  Google Scholar 

  13. Fagin J, Friedman R, Fireman P. Allergic rhinitis. Pediatr Clin North Am 1981; 28: 797–806

    PubMed  CAS  Google Scholar 

  14. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108(5 Suppl.): S147–334

    Article  PubMed  CAS  Google Scholar 

  15. American Academy of Allergy, Asthma & Immunology. The allergy report. Volume 2: diseases of the atopic diathesis. Milwaukee (WI): American Academy of Allergy, Asthma & Immunology, 2000

    Google Scholar 

  16. Blaiss M. Current concepts and therapeutic strategies for allergic rhinitis in school-age children. Clin Ther 2004; 26: 1876–89

    Article  PubMed  Google Scholar 

  17. Lai L, Casale TB, Stokes J. Pediatric allergic rhinitis: treatment. Immunol Allergy Clin N Am 2005; 25: 283–99

    Article  Google Scholar 

  18. Ramadan HH. Pediatric sinusitis: update. J Otolaryngol 2005; 34Suppl. 1: S14–7

    PubMed  Google Scholar 

  19. Slavin RG, Spector SL, Bernstein IL, et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol 2005; 116: S13–47

    Article  PubMed  Google Scholar 

  20. Krouse JH, Brown RW, Fineman SM, et al. Asthma and the unified airway. Otolaryngol Head Neck Surg 2007; 136: S75–106

    Article  PubMed  Google Scholar 

  21. Cowart BJ, Flynn-Rodden K, McGeady SJ, et al. Hyposmia in allergic rhinitis. J Allergy Clin Immunol 1993; 91: 747–51

    Article  PubMed  CAS  Google Scholar 

  22. Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children’s learning. Ann Allergy 1993; 71: 121–6

    PubMed  CAS  Google Scholar 

  23. Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007; 120: 381–7

    Article  PubMed  Google Scholar 

  24. Blaiss MS. Antihistamines: treatment selection criteria for pediatric seasonal allergic rhinitis. Allergy Asthma Proc 2005; 26: 95–102

    PubMed  CAS  Google Scholar 

  25. Bender BG, Milgrom H. Comparison of the effects of fluticasone propionate aqueous nasal spray and loratadine on daytime alertness and performance in children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004; 92: 344–9

    Article  PubMed  CAS  Google Scholar 

  26. Bender BG. Cognitive effects of allergic rhinitis and its treatment. Immunol Allergy Clin N Am 2005; 25: 301

    Article  Google Scholar 

  27. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000; 55: 116–34

    Article  PubMed  Google Scholar 

  28. Scadding GK. Corticosteroids in the treatment of pediatric allergic rhinitis. J Allergy Clin Immunol 2001; 108Suppl. 1: S59–64

    Article  PubMed  CAS  Google Scholar 

  29. Parikh A, Scadding GK. Seasonal allergic rhinitis [published erratum appears in BMJ 1997; 315: 42]. BMJ 1997; 314: 1392–5

    Article  PubMed  CAS  Google Scholar 

  30. Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf 2003; 26: 863–93

    Article  PubMed  CAS  Google Scholar 

  31. Cutler DL, Banfield C, Affrime MB. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr Asthma Allergy Immunol 2006; 19: 146–53

    Article  Google Scholar 

  32. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997; 19: 1330–9

    Article  PubMed  CAS  Google Scholar 

  33. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000 Feb; 105(2): E22

    Article  PubMed  CAS  Google Scholar 

  34. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics 1993; 92: 594–9

    PubMed  CAS  Google Scholar 

  35. Meltzer EO, Berger WE, Berkowitz RB, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 107–14

    Article  PubMed  CAS  Google Scholar 

  36. Hughes K, Glass C, Ripchinski M, et al. Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy 2003; 58: 380–5

    Article  PubMed  CAS  Google Scholar 

  37. Gurevich F, Glass C, Davies M, et al. The effect of intranasal steroid budesonide on the congestion-related sleep disturbance and daytime somnolence in patients with perennial allergic rhinitis. Allergy Asthma Proc 2005; 26: 268–74

    PubMed  CAS  Google Scholar 

  38. Beconase® [package insert]. Research Triangle Park (NC): GlaxoSmithKline, 2006

  39. Rhinocort® [package insert]. Wilmington (DE): AstraZeneca LP, 2006

  40. Nasarel® [package insert]. Miami (FL): Ivax Laboratories Inc., 2006

  41. Flonase® [package insert]. Research Triangle Park (NC): GlaxoSmithKline, 2006

  42. Veramyst® [package insert]. Research Triangle Park (NC): GlaxoSmithKline, 2007

  43. Nasacort® [package insert]. Bridgewater (NJ): Sanofi-Aventis U.S., 2006

  44. Nasonex® [package insert]. Kenilworth (NJ): Schering Corporation, 2005

  45. Holm A, Dijkstra M, Kleinjan A, et al. Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: effects of single allergen challenge. J Allergy Clin Immunol 2001; 107: 627–33

    Article  PubMed  CAS  Google Scholar 

  46. Graft D, Aaronson D, Chervinsky P, et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996; 98: 724–31

    Article  PubMed  CAS  Google Scholar 

  47. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998; 317: 1624–9

    Article  PubMed  CAS  Google Scholar 

  48. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002; 89: 479–84

    Article  PubMed  CAS  Google Scholar 

  49. Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol 1999; 104: S144–9

    Article  PubMed  CAS  Google Scholar 

  50. Berger WE, Nayak AS, Staudinger HW. Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis. Ann Pharmacother 2005; 39: 1984–9

    Article  PubMed  CAS  Google Scholar 

  51. Drouin M, Yang WH, Bertrand B, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone diproprionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 1996; 77: 153–60

    Article  PubMed  CAS  Google Scholar 

  52. Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group. Ann Allergy Asthma Immunol 1997; 79: 237–4

    Article  PubMed  CAS  Google Scholar 

  53. Hebert JR, Nolop K. Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy 1996; 51: 569–76

    PubMed  CAS  Google Scholar 

  54. Berkowitz RB, Roberson S, Zorra J, et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc 1999; 20: 167–72

    Article  PubMed  CAS  Google Scholar 

  55. Anon JB. Acute bacterial rhinosinusitis in pediatric medicine: current issues in diagnosis and management. Paediatr Drugs 2003; 5Suppl. 1: 25–33

    PubMed  Google Scholar 

  56. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate [abstract]. Pediatrics 2000; 105: E23

    Article  PubMed  CAS  Google Scholar 

  57. Class labeling for intranasal and orally inhaled corticosteroid containing drug products regarding the potential for growth suppression in children division of pulmonary drug products. US Food and Drug Administration [online]. Available from URL: http://www.fda.gov [Accessed 2008 Apr 17]

  58. Daley-Yates PT, Richards HR. Pharmacokinetic and pharmacodynamic relationships for intranasal corticosteroids (INCS). J Allergy Clin Immunol 2001; 107: S313

    Google Scholar 

  59. Onrust SV, Lamb HM. Mometasone furoate: a review of its intranasal use in allergic rhinitis. Drugs 1998; 56: 725–45

    Article  PubMed  CAS  Google Scholar 

  60. Skoner DP, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 2003; 90: 56–62

    Article  PubMed  CAS  Google Scholar 

  61. Wolthers OD, Pedersen S. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids. Acta Paediatr 1993; 82: 635–40

    PubMed  CAS  Google Scholar 

  62. Wolthers OD, Pedersen S. Knemometric assessment of systemic activity of once daily intranasal dry-powder budesonide in children. Allergy 1994; 49: 96–9

    Article  PubMed  CAS  Google Scholar 

  63. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol 1999; 104: 948–52

    Article  PubMed  CAS  Google Scholar 

  64. Sarsfield JK, Thomson GE. Flunisolide nasal spray for perennial rhinitis in children. BMJ 1979; 2: 95–7

    Article  PubMed  CAS  Google Scholar 

  65. Kokron CM, Castro AS, Sole D, et al. Lysine-vasopressin in the evaluation of the hypothalamic-pituitary-adrenal axis in children with allergic rhinitis treated with intranasal beclomethasone dipropionate or oral prednisone. J Invest Allergol Clin Immunol 1997; 7: 51–6

    CAS  Google Scholar 

  66. Mansfield LE, Mendoza CP. Medium and long-term growth in children receiving beclomethasone dipropionate: a clinical experience. South Med J 2002; 95: 334–40

    PubMed  Google Scholar 

  67. Möller C, Ahlström H, Henricson KA, et al. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 2003; 33: 816–22

    Article  PubMed  Google Scholar 

  68. Agertoft L, Wolthers OD, Fuglsang G, et al. Nasal powder administration of budesonide for seasonal rhinitis in children and adolescents. Pediatr Allergy Immunol 1993; 4: 152–6

    Article  PubMed  CAS  Google Scholar 

  69. Nayak AS, Ellis MH, Gross GN, et al. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol 1998; 101: 157–62

    Article  PubMed  CAS  Google Scholar 

  70. Allen DB, Meltzer EO, Lemanske Jr RF, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002; 23: 407–13

    PubMed  CAS  Google Scholar 

  71. Fluticasone Propionate Collaborative Pediatric Working Group. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. J Pediatr 1994; 125: 628–34

    Article  Google Scholar 

  72. Galant SP, Melamed IR, Nayak AS, et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics 2003; 112: 96–100

    Article  PubMed  Google Scholar 

  73. Baena-Cagnani CE. Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf 2004; 27: 883–98

    Article  PubMed  CAS  Google Scholar 

  74. Scadding GK. Safety of intranasal steroids. Curr Opin ENT. London: Royal Society of Medicine publications, 2002

    Google Scholar 

  75. Allen DB. Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol 2000; 106: S179–90

    Article  PubMed  CAS  Google Scholar 

  76. Minshall E, Ghaffar O, Cameron L, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998; 118: 648–54

    PubMed  CAS  Google Scholar 

  77. Holm AF, Fokkens WJ, Godthelp T, et al. A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: a safety and biopsy study. Clin Otolaryngol 1998; 23: 69–73

    Article  PubMed  CAS  Google Scholar 

  78. De Sutter AIM, Lemiengre M, Campbell H. Antihistamines for the common cold. Cochrane Database Syst Rev 2003; (3): CD001267

    Google Scholar 

  79. Hore I, Georgalas C, Scadding G. Oral antihistamines for the symptom of nasal obstruction in persistent allergic rhinitis: a systematic review of randomized controlled trials. Clin Exp Allergy 2005; 35: 207–12

    Article  PubMed  CAS  Google Scholar 

  80. Wilken JA, Kane RL, Ellis AK, et al. A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91: 375–85

    Article  PubMed  CAS  Google Scholar 

  81. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003; 111: S835–42

    Article  PubMed  Google Scholar 

  82. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489–98

    Article  PubMed  CAS  Google Scholar 

  83. Claritin® [package insert]. Kenilworth (NJ): Schering Corporation, 2005

  84. Clarinex® [package insert]. Kenilworth (NJ): Schering Corporation, 2005

  85. Allegra® [package insert]. Kansas City (MO): Aventis Pharmaceuticals Inc, 2005

  86. Zyrtec® [package insert]. New York (NY): Pfizer Inc., 2006

  87. Astelin® [package insert]. Somerset (NJ): MedPointe Pharmaceuticals, Inc, 2006

  88. Herman D, Garay R, Le Gal M. A randomized double-blind placebo controlled study of azelastine nasal spray in children with perennial rhinitis. Int J Pediatr Otorhinolaryngol 1997; 39: 1–8

    Article  PubMed  CAS  Google Scholar 

  89. Haberal I, Corey JP. The role of leukotrienes in nasal allergy. Otolaryngol Head Neck Surg 2003; 129: 274–9

    Article  PubMed  Google Scholar 

  90. Ciprandi G, Tosca MA, Milanese M, et al. Antihistamines added to an antileukotriene in treating seasonal allergic rhinitis: histamine and leukotriene antagonism. Allergy Immunol 2004; 36: 67–70, 72

    Google Scholar 

  91. Singulair® [package insert]. Whitehouse Station (NJ): Merck & Co., Inc., 2005

  92. Razi C, Makirtas A, Harmanci K, et al. Effect of montelukast on symptoms and exhaled nitric oxide levels in 7- to 14-year-old children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006; 97: 767–74

    Article  PubMed  CAS  Google Scholar 

  93. Chen ST, Lu KH, Sun HL, et al. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2–6 yr. Pediatr Allergy Immunol 2006; 17: 49–54

    Article  PubMed  Google Scholar 

  94. Pullerits T, Praks L, Ristioja V, et al. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 949–55

    Article  PubMed  CAS  Google Scholar 

  95. Di Lorenzo G, Pacor ML, Pellitteri ME, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 2004; 34: 259–67

    Article  PubMed  Google Scholar 

  96. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; (1): CD001936

    Google Scholar 

  97. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003; 33: 206–10

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Editorial assistance in the preparation of this manuscript was provided by Sandra Westra and Matthew Cahill of Adelphi Eden Health Communications. Glenis Scadding is an advisory board member and lecturer for several pharmaceutical companies (GlaxoSmithKline, Schering-Plough, UCB Pharma MSD, ALK) which manufacture drugs for rhinitis and has also received grants for research from GlaxoSmithKline and MSD. Schering-Plough Corp. provided funding for the editorial support.

Author information

Authors and Affiliations

  1. Royal National Throat, Nose & Ear Hospital, Gray’s Inn Road, London, WC1X 8DA, UK

    Glenis Scadding

Authors
  1. Glenis Scadding
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Glenis Scadding.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scadding, G. Optimal Management of Nasal Congestion Caused by Allergic Rhinitis in Children. Pediatr-Drugs 10, 151–162 (2008). https://doi.org/10.2165/00148581-200810030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00148581-200810030-00004

Keywords

Search

Navigation